MX2020004730A - Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada. - Google Patents

Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.

Info

Publication number
MX2020004730A
MX2020004730A MX2020004730A MX2020004730A MX2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A
Authority
MX
Mexico
Prior art keywords
intraocular pressure
sustained
effect
extended duration
lowering intraocular
Prior art date
Application number
MX2020004730A
Other languages
English (en)
Inventor
Michael R Robinson
Marina Bejanian
Michelle Y Chen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2020004730A publication Critical patent/MX2020004730A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)

Abstract

En la presente invención, se describen métodos para el tratamiento de la presión intraocular (PIO) aumentada con implantes intraoculares intracamerales. La liberación controlada y sostenida de bimatoprost a la cámara anterior del ojo puede ser eficaz para tratar un ojo durante al menos un año o más para la reducción de la PIO.
MX2020004730A 2017-11-09 2018-11-09 Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada. MX2020004730A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US201862683337P 2018-06-11 2018-06-11
PCT/US2018/059910 WO2019094652A1 (en) 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Publications (1)

Publication Number Publication Date
MX2020004730A true MX2020004730A (es) 2020-08-13

Family

ID=64457124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004730A MX2020004730A (es) 2017-11-09 2018-11-09 Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.

Country Status (16)

Country Link
US (2) US20190192341A1 (es)
EP (1) EP3706717A1 (es)
JP (2) JP2021502366A (es)
KR (1) KR20200086289A (es)
CN (1) CN111315361A (es)
AU (1) AU2018366214A1 (es)
BR (1) BR112020009224A2 (es)
CA (1) CA3080908A1 (es)
CL (1) CL2020001183A1 (es)
CO (1) CO2020006924A2 (es)
IL (1) IL273946A (es)
MX (1) MX2020004730A (es)
PH (1) PH12020550550A1 (es)
RU (1) RU2020113494A (es)
SG (1) SG11202004126XA (es)
WO (1) WO2019094652A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351239B1 (en) * 2013-10-31 2020-04-01 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
CA3144406A1 (en) 2019-06-27 2020-12-30 Layerbio, Inc. Ocular device delivery methods and systems
KR20220151622A (ko) * 2020-02-06 2022-11-15 오큘라 테라퓨틱스, 인코포레이티드 안질환 치료를 위한 조성물 및 방법
AU2021305247A1 (en) 2020-07-10 2023-02-23 Allergan, Inc. Posterior chamber delivery device for sustained release implant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
DK2525776T3 (en) * 2010-01-22 2016-02-08 Allergan Inc Intracameral implants WITH depot preparation
US8715713B2 (en) * 2011-04-29 2014-05-06 Allergan, Inc. Solvent cast film sustained release latanoprost implant
EP3351239B1 (en) * 2013-10-31 2020-04-01 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
EP3076948B1 (en) * 2013-12-06 2020-11-18 Allergan, Inc. Intracameral implant for treatment of an ocular condition
WO2017015675A1 (en) * 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants

Also Published As

Publication number Publication date
WO2019094652A1 (en) 2019-05-16
JP2024032731A (ja) 2024-03-12
CO2020006924A2 (es) 2020-06-19
CA3080908A1 (en) 2019-05-16
CL2020001183A1 (es) 2020-11-06
IL273946A (en) 2020-05-31
AU2018366214A1 (en) 2020-05-14
EP3706717A1 (en) 2020-09-16
RU2020113494A (ru) 2021-12-09
SG11202004126XA (en) 2020-06-29
KR20200086289A (ko) 2020-07-16
PH12020550550A1 (en) 2021-03-22
BR112020009224A2 (pt) 2020-10-13
RU2020113494A3 (es) 2021-12-09
US20240130890A1 (en) 2024-04-25
CN111315361A (zh) 2020-06-19
JP2021502366A (ja) 2021-01-28
US20190192341A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MX2020004730A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
CY1120950T1 (el) Θεραπεια ινωσης
PH12018500658A1 (en) Methods of treating intraocular pressure with activators of tie-2
CO2017005624A2 (es) Composiciones oftálmicas estabilizadas de omega 3
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
IL277557A (en) Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases
PH12017550023A1 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
SG11202102820VA (en) Ophthalmic composition for treatment of dry eye disease
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
EA201790383A1 (ru) Композиции и способы лечения и профилактики инфекций области хирургического вмешательства
NZ746468A (en) Methods of treating ocular conditions
GB2541840A (en) Ophthalmic composition for the treatment of ocular infection
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
SG11202002640YA (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
EA035539B9 (ru) Офтальмологическая композиция для применения при лечении офтальмологических расстройств, связанных с изменениями роговично-конъюнктивальной поверхности
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2017007578A (es) Farmacoterapia para prevenir o tratar glaucoma.
SG10202110804WA (en) Methods of preventing or treating ophthalmic diseases
RU2014140798A (ru) Способ коррекции фиброзно-измененных фильтрационных подушек, возникающих в послеоперационном периоде при хирургии глаукомы
MX2020003550A (es) Anticuerpos monoclonales anti-trkb y metodos de uso.